Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Melanoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.